Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 von Scher, Howard I, Morris, Michael J, Stadler, Walter M, Higano, Celestia, Basch, Ethan, Fizazi, Karim, Antonarakis, Emmanuel S, Beer, Tomasz M, Carducci, Michael A, Chi, Kim N, Corn, Paul G, de Bono, Johann S, Dreicer, Robert, George, Daniel J, Heath, Elisabeth I, Hussain, Maha, Kelly, Wm Kevin, Liu, Glenn, Logothetis, Christopher, Nanus, David, Stein, Mark N, Rathkopf, Dana E, Slovin, Susan F, Ryan, Charles J, Sartor, Oliver, Small, Eric J, Smith, Matthew Raymond, Sternberg, Cora N, Taplin, Mary-Ellen, Wilding, George, Nelson, Peter S, Schwartz, Lawrence H, Halabi, Susan, Kantoff, Philip W, Armstrong, Andrew J

Volltext

A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate c... von Gao, Xin, Smith, Matthew Raymond, Scher, Howard I., Verholen, Frank, Adorjan, Patrick, Dissanayake, Manjari, Laccetti, Andrew Leonard

Volltext

Efficacy of subsequent treatments in patients who progressed to mCRPC following treatment with apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): A post-h... von Oudard, Stephane, Hadaschik, Boris A., Antoni, Laurent, Diels, Joris, Luccarini, Irene, Thilakarathne, Pushpike, Smith, Matthew Raymond, Small, Eric Jay

Volltext

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 202... von Gillessen, Silke, Bossi, Alberto, Davis, Ian D., de Bono, Johann, Fizazi, Karim, James, Nicholas D., Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Matthew, Sweeney, Christopher J., Tombal, Bertrand, Antonarakis, Emmanuel S., Aparicio, Ana M., Armstrong, Andrew J., Attard, Gerhardt, Beer, Tomasz M., Beltran, Himisha, Bjartell, Anders, Blanchard, Pierre, Bulbul, Muhammad, Caffo, Orazio, Chi, Kim N., Chowdhury, Simon, Clarke, Caroline S., Clarke, Noel, Daugaard, Gedske, De Santis, Maria, Duran, Ignacio, Eeles, Ross, Efstathiou, Jason, Evans, Christopher P., Fanti, Stefano, Feng, Felix Y., George, Dan, Gleave, Martin, Gravis, Gwenaelle, Halabi, Susan, Heinrich, Daniel, Herrmann, Ken, Higano, Celestia, Hofman, Michael S., Horvath, Lisa G., Hussain, Maha, Jereczek-Fossa, Barbara A., Jones, Rob, Kanesvaran, Ravindran, Kellokumpu-Lehtinen, Pirkko-Liisa, Khauli, Raja B., Klotz, Laurence, Logothetis, Christopher, Mahal, Brandon, Maluf, Fernando, Matheson, David, Mehra, Niven, Merseburger, Axel, Morgans, Alicia K., Morris, Michael J., Mrabti, Hind, Mukherji, Deborah, Murphy, Declan G., Murthy, Vedang, Nguyen, Paul L., Oh, William K., Ost, Piet, O’Sullivan, Joe M., Padhani, Anwar R., Pezaro, Carmel J., Poon, Darren M.C., Pritchard, Colin C., Rathkopf, Dana, Rubin, Mark A., Ryan, Charles J., Sade, Juan Pablo, Sartor, Oliver, Scher, Howard I., Sharifi, Nima, Skoneczna, Iwona, Soule, Howard, Spratt, Daniel E., Srinivas, Sandy, Sternberg, Cora N., Steuber, Thomas, Suzuki, Hiroyoshi, Sydes, Matthew R., Taplin, Mary-Ellen, Tilki, Derya, Türkeri, Levent, Uemura, Hiroji, Uemura, Hirotsugu, Vale, Claire L., van Oort, Inge, Vapiwala, Neha, Walz, Jochen, Yamoah, Kosj, Ye, Dingwei, Yu, Evan Y., Zapatero, Almudena, Zilli, Thomas, Omlin, Aurelius

Volltext

Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS tri... von Saad, Fred, Hussain, Maha H. A., Tombal, Bertrand F., Fizazi, Karim, Sternberg, Cora N., Crawford, E. David, Thiele, Silke, Li, Rui, Kuss, Iris, Joensuu, Heikki, Smith, Matthew Raymond

Volltext

Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study von Wang, Shanshan, Fu, Cheng, Zou, Qing, Li, Youyuan, He, Dalin, Wang, Shaogang, Wang, Hongkai, Smith, Matthew Raymond, Tombal, Bertrand F., Hussain, Maha H. A., Niu, Yi, Cai, Ling, Hu, Nan, Huang, Shiyun, Kapur, Shivani, Li, Rui, Kuss, Iris, Ye, Dingwei

Volltext

Darolutamide and time to pain progression by disease volume in ARASENS von Smith, Matthew Raymond, Tombal, Bertrand F., Saad, Fred, Fizazi, Karim, Sternberg, Cora N., Crawford, E. David, Aragon-Ching, Jeanny B., Schostak, Martin, Tutrone, Ronald, Mohamed, Ateesha F., Littleton, Natasha, Li, Rui, Srinivasan, Shankar, Hussain, Maha H. A.

Volltext

CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant pros... von Smith, Matthew Raymond, Agarwal, Neeraj, Todenhöfer, Tilman, Trepiakas, Redas, Lee, Jae-Lyun, Lithio, Andrew, Chapman, Sonya, Nacerddine, Karim, Sweeney, Christopher

Volltext

CYCLONE 3: A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-s... von Smith, Matthew Raymond, Matsubara, Nobuaki, McKay, Rana R., Piulats, Josep M., Todenhöfer, Tilman, Zhang, Tian, Fasnacht, Nicolas, Sherwood, Sarah, Johnston, Erica L., Schaverien, Clare, Lithio, Andrew, Nacerddine, Karim, Agarwal, Neeraj

Volltext

Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer von Pachynski, Russell Kent, Iannotti, Nicholas, Laccetti, Andrew Leonard, Carthon, Bradley Curtis, Chi, Kim N., Smith, Matthew Raymond, Vogelzang, Nicholas J., Tu, Wilson, Kwan, Edmond Michael, Wyatt, Alexander William, Villaluna, Karen, Younginger, Brett, Cesano, Alessandra

Volltext

Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormo... von Rezazadeh, Arash, Tombal, Bertrand F., Hussain, Maha H. A., Saad, Fred, Fizazi, Karim, Sternberg, Cora N., Crawford, E. David, Kapur, Shivani, Zhang, Weijiang, Ploeger, Bart, Li, Rui, Kuss, Iris, Zieschang, Carsten, Wittemer-Rump, Sabine, Smith, Matthew Raymond

Volltext

CYCLONE 1: A phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based c... von Agarwal, Neeraj, Oudard, Stephane, Piulats, Josep M., Schweizer, Michael Thomas, Flechon, Aude, Alonso Gordoa, Teresa, Nacerddine, Karim, Lithio, Andrew, Johnston, Erica L., Smith, Matthew Raymond

Volltext

Association of metastasis-free survival (MFS) and overall survival (OS) in nonmetastatic castration-resistant prostate cancer (nmCRPC) von Smith, Matthew Raymond, Mehra, Maneesha, Nair, Sandhya, Lawson, Joe, Small, Eric Jay

Volltext

CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant pro... von Smith, Matthew Raymond, Agarwal, Neeraj, Todenhöfer, Tilman, Piulats, Josep M., Lee, Jae-Lyun, Trepiakas, Redas, Rao, Arpit, Horvath, Lisa, Lithio, Andrew, Johnston, Erica L., Hulstijn, Maarten, Nacerddine, Karim, Sweeney, Christopher

Volltext

Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) i... von Small, Eric Jay, Chi, Kim N., Chowdhury, Simon, Bevans, Katherine B., Bhaumik, Amitabha, Saad, Fred, Chung, Byung, Karsh, Lawrence Ivan, Oudard, Stephane, De Porre, Peter, Brookman-May, Sabine D., McCarthy, Sharon Anne, Mundle, Suneel, Uemura, Hirotsugu, Smith, Matthew Raymond, Agarwal, Neeraj

Volltext

Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS von Fizazi, Karim, Shore, Neal D., Smith, Matthew Raymond, Ramos, Rodrigo, Jones, Robert J., Niegisch, Guenter, Vjaters, Egils, Ortiz, Jorge A., Liang, Steve, Wang, Yuan, Srinivasan, Shankar, Sarapohja, Toni, Verholen, Frank

Volltext

Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC) von Halabi, Susan, Roy, Akash, Guo, Siyuan S, Rydzewska, Larysa, Godolphin, Peter, Hussain, Maha H. A., Tangen, Catherine, Thompson, Ian, Xie, Wanling, Carducci, Michael Anthony, Smith, Matthew Raymond, Morris, Michael J., Gravis, Gwenaelle, Dearnaley, David P., Verhagen, Paul, Goto, Takayuki, Tierney, Jayne F., James, Nicholas D., Buyse, Marc E., Sweeney, Christopher

Volltext

Digital histopathology-based multimodal artificial intelligence scores predict risk of progression in a randomized phase III trial in patients with nonmetastatic castration-resista... von Feng, Felix Y, Smith, Matthew Raymond, Saad, Fred, Mobadersany, Pooya, Tian, Shaozhou Ken, Yip, Stephen S. F., Greshock, Joel, Khan, Najat, Yu, Margaret K., McCarthy, Sharon, Brookman-May, Sabine D., Todorovic, Tamara, Yamashita, Rikiya, Huang, Huei-Chung Rebecca, Showalter, Timothy N, Mitani, Akinori, Esteva, Andre, Small, Eric Jay

Volltext

The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC) von Halabi, Susan, Guo, Siyuan S, Roy, Akash, Rydzewska, Larysa, Godolphin, Peter, Hussain, Maha H. A., Tangen, Catherine, Thompson, Ian, Xie, Wanling, Carducci, Michael Anthony, Smith, Matthew Raymond, Morris, Michael J., Gravis, Gwenaelle, Dearnaley, David P., Verhagen, Paul, Goto, Takayuki, James, Nicholas D., Parmar, Mahesh, Buyse, Marc E., Sweeney, Christopher

Volltext

AI-enabled analysis of H&E-stained prostate cancer tissue images: Assessing risk for metastasis prior to apalutamide (APA) treatment of patients with non-metastatic castration-resi... von Mobadersany, Pooya, Tian, Shaozhou Ken, Yip, Stephen S. F., Greshock, Joel, Khan, Najat, Yu, Margaret K., McCarthy, Sharon, Brookman-May, Sabine D., Muhammad, Hassan, Xie, Chensu, Huang, Wei, Basu, Hirak S, Wilding, George, Jain, Parag, Roy, Rajat, Small, Eric Jay, Saad, Fred, Smith, Matthew Raymond

Volltext